<p>兰顿制药公司（纳斯达克股票代码：LTRN - 获取免费报告）在六月份的短期利空大幅下降。截至 6 月 15 日，短期利空股票总数为 333,500 股，较 5 月 31 日的 419,800 股下降了 20.6%。根据平均每日交易量为 163,200 股，目前的短期利空比率为 2.0 天。公司股票中约有 4.2% 被做空。</p>
<p>获取 <strong>兰顿制药</strong> 警报：</p>
<h2>内部买卖</h2>
<ul>
<li>8 家股价低于 10 美元的最佳人工智能股票</li>
</ul>
<p>相关新闻中，主要股东 Aaron G.L. Fletcher 于 5 月 23 日星期四以每股 6.25 美元的平均价格出售了兰顿制药公司的 10,000 股股票，总交易额为 62,500.00 美元。交易完成后，该内部人士现持有公司股票的 59,326 股，价值约为 370,787.50 美元。该交易已在证券交易委员会的法律文件中披露，可通过此链接查看。目前公司股票的 6.92% 由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一家机构投资者最近增加了其在兰顿制药公司股票中的持仓。根据最新提交给证券交易委员会的 13F 文件，Meridian Wealth Management LLC 在第四季度将其在兰顿制药公司（纳斯达克股票代码：LTRN - 免费报告）的持股增加了 18.0%，在此期间购入了额外的 3,000 股。Meridian Wealth Management LLC 在最新提交给证券交易委员会的文件中拥有公司股票 19,660 股，价值 84,000 美元。机构投资者和对冲基金共持有公司股票的 28.62%。</p>
<h2>分析师设定新的价格目标</h2>
<p>另外，HC Wainwright 在 4 月 25 日的报告中重申了对兰顿制药的 “中性” 评级。</p>
<p>获取我们对兰顿制药的最新股票分析</p>
<h2>兰顿制药股价表现</h2>
<p>LTRN 股票周五开盘价为 4.67 美元。该公司的市值为 5025 万美元，市盈率为-2.87，贝塔系数为 1.61。兰顿制药的一年最低价为 2.38 美元，最高价为 11.99 美元。该公司的五十日移动平均价为 5.64 美元，两百日移动平均价为 5.52 美元。</p>
<p>兰顿制药（纳斯达克股票代码：LTRN - 获取免费报告）最近公布了截至 5 月 9 日的季度财报。公司报告的每股亏损为（0.51）美元，低于市场预期的（0.43）美元。卖方分析师平均预计，兰顿制药今年将实现每股-2.23 美元的亏损。</p>
<h2>兰顿制药公司简介（获取免费报告）</h2>
<p>兰顿制药公司是一家临床阶段的生物技术公司，专注于人工智能、机器学习和基因组数据，以简化药物开发流程。其产品管线包括 LP-300，正在进行第 2 期临床试验，用于非吸烟者非小细胞肺腺癌的联合治疗；LP-184，正在进行第 1 期临床试验，用于胰腺、乳腺、膀胱和肺癌、胶质母细胞瘤和其他中枢神经系统癌症的治疗；以及 LP-284，正在进行第 1 期临床试验，用于非霍奇金淋巴瘤的治疗，包括曼特尔细胞淋巴瘤和双击淋巴瘤。</p>
<h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票比兰顿制药更好</li>
<li>高股息房地产投资信托：它们是多样化的理想方式吗？</li>
<li>瓦尔格林斯股价暴跌背后的原因：投资者下一步该怎么做</li>
<li>寻找并有利可图地交易 52 周最低股票</li>
<li>MarketBeat 周评 - 6/24 - 6/28</li>
<li>想要从下降趋势中获利？下降趋势，解释。</li>
<li>通用磨坊股价在 2024 财年第四季度营收不及预期后下跌</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 拜登接班的几率提高了 105%！（来自自由港协会）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg4"/></p>
<h2>您现在是否应该投资 1,000 美元购买兰顿制药？</h2>
<p>在考虑兰顿制药之前，您可能想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们建议客户购买的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而兰顿制药不在名单上。</p>
<p>虽然兰顿制药目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

挚文集团

<p>挚文集团（NASDAQ:LTRN）在六月份经历了空头头寸的显著下降，与五月相比，空头头寸下降了 20.6%。该公司的股票目前有 4.2% 被做空，空头头寸比率为 2.0 天。此外，一位主要股东出售了 1 万股挚文集团的股票。机构投资者和对冲基金拥有该公司 28.62% 的股份。分析师们给予挚文集团中立评级。该公司专注于利用人工智能和基因组数据进行药物开发</p>

<p>Lantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 333,500 shares, a decline of 20.6% from the May 31st total of 419,800 shares. Based on an average daily trading volume, of 163,200 shares, the short-interest ratio is currently 2.0 days. Approximately 4.2% of the company's stock are short sold.</p>
<div class="lb-trans"><p>兰顿制药公司（纳斯达克股票代码：LTRN - 获取免费报告）在六月份的短期利空大幅下降。截至 6 月 15 日，短期利空股票总数为 333,500 股，较 5 月 31 日的 419,800 股下降了 20.6%。根据平均每日交易量为 163,200 股，目前的短期利空比率为 2.0 天。公司股票中约有 4.2% 被做空。</p>
</div><p>Get <strong>Lantern Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>兰顿制药</strong> 警报：</p>
</div><h2>Insider Buying and Selling</h2>
<ul>
<li>8 Best Artificial Intelligence Stocks Under $10</li>
</ul>
<div class="lb-trans"><h2>内部买卖</h2>
<ul>
<li>8 家股价低于 10 美元的最佳人工智能股票</li>
</ul>
</div><p>In related news, major shareholder Aaron G.L. Fletcher sold 10,000 shares of Lantern Pharma stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $6.25, for a total transaction of $62,500.00. Following the sale, the insider now owns 59,326 shares of the company's stock, valued at approximately $370,787.50. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this link. 6.92% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>相关新闻中，主要股东 Aaron G.L. Fletcher 于 5 月 23 日星期四以每股 6.25 美元的平均价格出售了兰顿制药公司的 10,000 股股票，总交易额为 62,500.00 美元。交易完成后，该内部人士现持有公司股票的 59,326 股，价值约为 370,787.50 美元。该交易已在证券交易委员会的法律文件中披露，可通过此链接查看。目前公司股票的 6.92% 由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>An institutional investor recently raised its position in Lantern Pharma stock. Meridian Wealth Management LLC increased its holdings in Lantern Pharma Inc. (NASDAQ:LTRN - Free Report) by 18.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 19,660 shares of the company's stock after buying an additional 3,000 shares during the period. Meridian Wealth Management LLC owned about 0.18% of Lantern Pharma worth $84,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 28.62% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近增加了其在兰顿制药公司股票中的持仓。根据最新提交给证券交易委员会的 13F 文件，Meridian Wealth Management LLC 在第四季度将其在兰顿制药公司（纳斯达克股票代码：LTRN - 免费报告）的持股增加了 18.0%，在此期间购入了额外的 3,000 股。Meridian Wealth Management LLC 在最新提交给证券交易委员会的文件中拥有公司股票 19,660 股，价值 84,000 美元。机构投资者和对冲基金共持有公司股票的 28.62%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Separately, HC Wainwright reissued a &#34;neutral&#34; rating on shares of Lantern Pharma in a report on Thursday, April 25th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 4 月 25 日的报告中重申了对兰顿制药的 “中性” 评级。</p>
</div><p><strong>Get Our Latest Stock Analysis on Lantern Pharma</strong></p>
<div class="lb-trans"><p>获取我们对兰顿制药的最新股票分析</p>
</div><h2>Lantern Pharma Price Performance</h2>
<div class="lb-trans"><h2>兰顿制药股价表现</h2>
</div><p>Shares of LTRN stock opened at $4.67 on Friday. The firm has a market cap of $50.25 million, a P/E ratio of -2.87 and a beta of 1.61. Lantern Pharma has a 1-year low of $2.38 and a 1-year high of $11.99. The firm has a fifty day moving average of $5.64 and a two-hundred day moving average of $5.52.</p>
<div class="lb-trans"><p>LTRN 股票周五开盘价为 4.67 美元。该公司的市值为 5025 万美元，市盈率为-2.87，贝塔系数为 1.61。兰顿制药的一年最低价为 2.38 美元，最高价为 11.99 美元。该公司的五十日移动平均价为 5.64 美元，两百日移动平均价为 5.52 美元。</p>
</div><p>Lantern Pharma (NASDAQ:LTRN - Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). On average, sell-side analysts expect that Lantern Pharma will post -2.23 EPS for the current year.</p>
<div class="lb-trans"><p>兰顿制药（纳斯达克股票代码：LTRN - 获取免费报告）最近公布了截至 5 月 9 日的季度财报。公司报告的每股亏损为（0.51）美元，低于市场预期的（0.43）美元。卖方分析师平均预计，兰顿制药今年将实现每股-2.23 美元的亏损。</p>
</div><h2>Lantern Pharma Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>兰顿制药公司简介（获取免费报告）</h2>
</div><p>Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.</p>
<div class="lb-trans"><p>兰顿制药公司是一家临床阶段的生物技术公司，专注于人工智能、机器学习和基因组数据，以简化药物开发流程。其产品管线包括 LP-300，正在进行第 2 期临床试验，用于非吸烟者非小细胞肺腺癌的联合治疗；LP-184，正在进行第 1 期临床试验，用于胰腺、乳腺、膀胱和肺癌、胶质母细胞瘤和其他中枢神经系统癌症的治疗；以及 LP-284，正在进行第 1 期临床试验，用于非霍奇金淋巴瘤的治疗，包括曼特尔细胞淋巴瘤和双击淋巴瘤。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Lantern Pharma</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票比兰顿制药更好</li>
<li>高股息房地产投资信托：它们是多样化的理想方式吗？</li>
<li>瓦尔格林斯股价暴跌背后的原因：投资者下一步该怎么做</li>
<li>寻找并有利可图地交易 52 周最低股票</li>
<li>MarketBeat 周评 - 6/24 - 6/28</li>
<li>想要从下降趋势中获利？下降趋势，解释。</li>
<li>通用磨坊股价在 2024 财年第四季度营收不及预期后下跌</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Odds of Biden Replacement Up 105%! (From The Freeport Society)(Ad)</p>
<div class="lb-trans"><p>→ 拜登接班的几率提高了 105%！（来自自由港协会）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8588&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Lantern Pharma right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买兰顿制药？</h2>
</div><p>Before you consider Lantern Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑兰顿制药之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantern Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们建议客户购买的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而兰顿制药不在名单上。</p>
</div><p>While Lantern Pharma currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然兰顿制药目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Lantern Pharma Inc.（纳斯达克股票代码：LTRN）的空头头寸显著下降